{"name":"Vivozon, Inc.","slug":"vivozon-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"VVZ-149 Injections","genericName":"VVZ-149 Injections","slug":"vvz-149-injections","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"VVZ-149 Injections","genericName":"VVZ-149 Injections","slug":"vvz-149-injections","phase":"phase_3","mechanism":"VVZ-149 Injections is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOOGRESHl4bHp1Uzh6bi1Kcnhqd0ZHWlV6aV9LbWtBWEI0RndiakJPaEhrUnlMVU5FWnp0Q09IdE8taHhvaXBSUFFvSU5aMkxnR1lBTElVbVhRNTU4eDZpSWF4VXVVOEZPb0cwMWF6NjFyMGpsUk1kZTZmVHFtOUF1WdIBlAFBVV95cUxQMTVRbFF6N0pWd2Myemt0QU94VkRWZDVaT0tDbF9CN0taazgwaXQzYm10aU05Z2ZjU3ZHRWk0N3FvV2FTdHhieWI4b3BkejUzYW56OFFzTzdMSVE4QUhHdVNUQlRiZ2hicWZNeG1SaDJfUDR3b3o4MmVWaWctUk1rZHJnS1Z3eHVZTHVRWUMzbDhHUnNE?oc=5","date":"2025-10-14","type":"pipeline","source":"Chosunbiz","summary":"Vivozon Pharm raises 50 billion won to boost Onapraju commercialization in Korea - CHOSUNBIZ - Chosunbiz","headline":"Vivozon Pharm raises 50 billion won to boost Onapraju commercialization in Korea - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOYk13ZmlBeG16V1NIQ2JDU1FBVVFZdGVxRmRDWnEtMXpiajRLcEM5N3hpbmdGcnJMcWhXalctMVdfYlFkdDZIeW5YRWx3SGE0ZmNaVEFhVkxwTWs5Z0hCcElib0VJRHJzWXpraG1YeFBXNDRVX0tnMnRPeGM0UmFFU05GLUpqVi1sOWprM0dkMU5zelRzTkx5SXhESjJPM05BVEhNcW1R?oc=5","date":"2025-07-01","type":"deal","source":"BioWorld News","summary":"Abion strikes $1.3B antibody drug deal with unidentified partner - BioWorld News","headline":"Abion strikes $1.3B antibody drug deal with unidentified partner","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE95MDFWZzNwQUhETkdNWXRuRjU4Z1ZMbG5lcXRiNlBLeHY5NWVUdm1qSzNBWEhUQUN0MkFqM1daT181ZWFHNnRXbmhfQk4zT01OQnRWdWV4M19YQUtXVVBxQkRuWmk0dThjZGwtQ0RR0gFyQVVfeXFMUE4xczIyTVRubUItTVZZLXBfNjBYUUwxb1IwSzJWV01fdkdqS0huWk5vMEZPUG51QlEtdGRaM2gwdWlfMFA1c3h1NUxkMjBnT29fSDlibWVWNmRVdVNJQ0VuYzg0ZGZEZmlzYmdDQ0NfUEVR?oc=5","date":"2025-04-04","type":"trial","source":"koreabiomed.com","summary":"Vivozon launches non-opioid back pain trial in Korea, eyes US phase 3 wrap in 3 years - koreabiomed.com","headline":"Vivozon launches non-opioid back pain trial in Korea, eyes US phase 3 wrap in 3 years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPZEViNzNRaWx2V2dVRXRQZHVCVkVpTjVWNDk2V1NjSjVKb09xM2p4R3NIbm14STRCY05DQjhLNEZYOUZiVUJtUkhNaTlOejNyTmFrbXhvdDY4b09DNGtBZVhzb0FMNlE3d3dmUVhvMzlqeE5jWUJTUHd6dXA3NkFJcTQ3TW81dkQ3STNodXZHbGlwZTZsZ1RRQ1NZU2N2Y0FyOW14eHZfb29QTk5abEZ5SzN6dGkyaExuZVdnR1B0Tk5qR0hlTWdPQVZpYVc4NWlvVmVfV24tM3FhM1lFQ1RkT1ZJZkFjZw?oc=5","date":"2025-02-18","type":"regulatory","source":"prnewswire.com","summary":"VIVOZON Pharmaceutical Obtains MFDS Approval for UNAFRA Inj.: A Breakthrough Non-Opioid analgesic - prnewswire.com","headline":"VIVOZON Pharmaceutical Obtains MFDS Approval for UNAFRA Inj.: A Breakthrough Non-Opioid analgesic","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1UN01sS0dSSnUyWG0wcUhYME1idFdpQl9aTVZUc25KMkdTTWE5ZnBaXzB6M0NHSVRXREIyNE56WGMtN1IzSnVHeG9xYlFBOHIzZzEyLWZfeDZXSGZIcVh2T2NxZTZNZFZJZFFpQmhR0gFyQVVfeXFMT1p5ck0tejBLa0U0SU4zQVdJZlBEamRhX19GSXdSY3poLTJ2dkZaY2pKeWdwQjdJZy10THNKMndUNTRTSjVkb0NHU0lkN0hjRFVKc1VuTHdDY2dSMm1UZFM5OU5wQnhpbnU5UnFnQUJ3aW5R?oc=5","date":"2025-01-24","type":"patent","source":"koreabiomed.com","summary":"Vivozon’s non-narcotic pain reliever VVZ-2471 gets Chinese patent - koreabiomed.com","headline":"Vivozon’s non-narcotic pain reliever VVZ-2471 gets Chinese patent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1Pbk9uOXhwNWxPOXpFWXBDSXB5MWc0aHpzMmtkaVNOazIwR2F6RE5lMWF4aUhuZG4tM2syQXd1T0JIZ3BuYWNvbmpkcnZuZGFPeFNzaUtzUkM4c1ZzZV9yQkw2dHZPcE9IM0lRRG930gFyQVVfeXFMTUdtTVo0VFFlNndKWDdDdW1TUHF0aUlXb29MYmxUOVRhamJ2SmduNWh3M3RoTTVuWXluc1VyRF82Si1DNnNQblhNSFhvOFZHTGdtVnhoVGx1M2V3SkcyY3NDeFVwX2pZOVRWTG1PMEVlOXJ3?oc=5","date":"2023-08-03","type":"pipeline","source":"koreabiomed.com","summary":"Vivozon applies for preliminary review for non-narcotic painkiller - koreabiomed.com","headline":"Vivozon applies for preliminary review for non-narcotic painkiller","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5HOF9lc2hhaF9iWUNMVUE1cWZDVmFOLUVRY0FlRTRqeEpfazRmSnI4WE1YTEhmZmJiOFh0UENVSS1UM25OaXUtRS1TZUZORlZiUks2RnV3amJiaHBUT2ZvREp0RDNObGJsallRMTdR0gFyQVVfeXFMT2xyNEY5eUpTaXJjZDAtdTg5Y0ZFNVhWb1QyYUVqMTFPZXJVZ0ZoSVlPcmpuZnhrSzJpZ2NKTUV3NzE1Xy1ScjIzZVlMLVZmOFo3UnFhNEc0M0tqNFlJSG95WGZJdnBpTjc0aFhMck5wWE1n?oc=5","date":"2023-02-08","type":"trial","source":"koreabiomed.com","summary":"Vivozon’s non-narcotic painkiller proves benefit in phase 3 study - koreabiomed.com","headline":"Vivozon’s non-narcotic painkiller proves benefit in phase 3 study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5WWWhkbFdSeHFtZUxHenh3TU1pbVhEQy1EcmJiUUhOTEVTWHNtNnZ6NDNaLWFja2c4VWloMV9ZYzVVQ2xTNXJIc3NhRHNqUHpNTWdadWlfTmpoemdGVkctVHlXTFpBUk9Kbkh4bdIBcEFVX3lxTFBQLVJJRzdSMjZERUhRaHdhbE9YS3o3UzZvYThDcXg2Mi1jQkRMOTMtZWpvdWthckFvdG8wOGVORE5zcDJaeU1TTjhrZ2k1enFnQ09YSXZxQzUtdEJJZGV2cWZGMU0zTVFCMjlsMkxLbjc?oc=5","date":"2020-09-28","type":"trial","source":"koreabiomed.com","summary":"‘Vivozon’s Inist Bio takeover boosts nonnarcotic painkiller trial’ - koreabiomed.com","headline":"‘Vivozon’s Inist Bio takeover boosts nonnarcotic painkiller trial’","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}